A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

Inclusion Criteria: In order to be eligible to participate in this study, a patient must meet all of thefollowing criteria:

• Patients with: a diagnosis of AML and related precursor neoplasms according toICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A).Patients may have had previous treatment with erythropoiesis stimulating agents (ESA)for an antecedent phase of MDS. ESAs must be stopped at least two weeks beforeregistration.
• Patients 18 years and older who are considered not fit for intensive chemotherapy orwho decline the option of intensive chemotherapy.
• WHO performance status 0, 1 or 2 (appendix E).
• Adequate renal and hepatic functions unless clearly disease related as indicated bythe following laboratory values:
• Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min;calculated by the Cockcroft Gault formula or measured by 24 hours urinecollection.
• Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-relatedor due to Gilbert's syndrome.
• Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
• Male subjects who are sexually active, must agree, from Study Day 1 until at least 90days after the last dose of study drug, to practice the protocol specifiedcontraception. Male subjects must agree to refrain from sperm donation from initialstudy drug administration through at least 90 days after the last dose of study drug.
• Female subjects must be either postmenopausal defined as: Age >55 years with no mensesfor ≥12 months, without an alternative medical cause. OR willing and able to useadequate contraception during and until 180 days after the last protocol treatment.
• Written informed consent.
• Patient is capable of giving informed consent.
• Patient agrees not to participate in another interventional study while on treatmentwithout approval of the (co-) Principal Investigator.

Exclusion Criteria: A patient who meets any of the following criteria cannot be included in this study:

• Acute promyelocytic leukemia.
• Myelodysplastic syndrome (MDS).
• Patients previously treated for AML or MDS (any anti-leukemic therapy includinginvestigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2)hydroxyurea (hydroxyurea is allowed for the control of peripheral leukemic blasts inpatients with leukocytosis).
• Diagnosis of any previous or concomitant malignancy is an exclusion criterion:
• except when the patient successfully completed treatment (chemotherapy and/orsurgery and/or radiotherapy) with curative intent for this malignancy at least 24months prior to registration;
• except for basal and squamous cell carcinoma of the skin or in situ carcinoma ofthe cervix.
• Blast crisis of chronic myeloid leukemia.
• Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes,infection, hypertension, pulmonary disease etc.).
• Cardiac dysfunction as defined by:
• Myocardial infarction within the last 3 months of study entry, or
• Reduced left ventricular function with an ejection fraction < 40% as measured byMUGA scan or echocardiogram, or
• Unstable angina or New York Heart Association (NYHA) grade IV congestive heartfailure (see Appendix G), or
• Unstable cardiac arrhythmias.
• History of stroke or intracranial haemorrhage within 6 months prior to registration.
• Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncturerequired to investigate CNS involvement).
• History of non-compliance to medical regimens or considered unreliable with respect tocompliance.
• Senile dementia, mental impairment or any other psychiatric disorder that prohibitsthe patient from understanding and giving informed consent.
• Current concomitant chemotherapy, radiation therapy, or immunotherapy; other thanhydroxyurea.
• Any psychological, familial, sociological or geographical condition potentiallyhampering compliance with the study protocol and follow-up schedule.
• Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrateswith a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment).Please check with Appendix I.
• Intolerability, contra-indication or allergy to one of the study drugs.